Risk stratification in acute pulmonary embolism with heart-type fatty acid–binding protein: A meta-analysis

Bajaj, Archna; Rathor, Parul; Sehgal, Vasudha; Shetty, Ajay; Kabak, Besher; Hosur, Srikanth

doi:10.1016/j.jcrc.2015.05.026

Cited by 31 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Heart-type fatty acid-binding protein (H-FABP), an early and sensitive marker of myocardial injury, provides prognostic information in acute PE, both in unselected [198,199] and normotensive patients [200,201]. In a meta-analysis investigating 1680 patients with PE, H-FABP concentrations ⩾6 ng/mL were associated with an adverse short-term outcome (OR 17.7, 95% CI 6.0-51.9) and all-cause mortality (OR 32.9, 95% CI 8.8-123.2) [202].…”

Section: Laboratory Biomarkers 531 Markers Of Myocardial Injurymentioning

confidence: 99%

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

et al. 2019

View full text Add to dashboard Cite

show abstract

Section: Laboratory Biomarkers 531 Markers Of Myocardial Injurymentioning

confidence: 99%

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Some authors state additional benefits of combining H-FABP with high-sensitive troponins [37,38], whereas, others do not conclude any incremental benefit of H-FABP on top of cardiac troponins for diagnosing acute myocardial infarction [42,51,52]. Regarding pulmonary embolism (PE), several publications describe the use of H-FABP for risk stratification due to its role as an early indicator of right-ventricular strain [53][54][55]. A strong correlation with the risk of major adverse events and mortality was demonstrated, and even the 2019 ESC Guidelines on the diagnosis and management of acute PE mention the use of H-FABP for risk stratification, despite the fact that prospective trials are still missing [56].…”

Section: H-fabp As a Biomarker In Heart Failurementioning

confidence: 99%

Heart-Type Fatty Acid-Binding Protein (H-FABP) and Its Role as a Biomarker in Heart Failure: What Do We Know So Far?

Rezar

Jirak

Gschwandtner

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Heart failure (HF) remains one of the leading causes of death to date despite extensive research funding. Various studies are conducted every year in an attempt to improve diagnostic accuracy and therapy monitoring. The small cytoplasmic heart-type fatty acid-binding protein (H-FABP) has been studied in a variety of disease entities. Here, we provide a review of the available literature on H-FABP and its possible applications in HF. Methods: Literature research using PubMed Central was conducted. To select possible studies for inclusion, the authors screened all available studies by title and, if suitable, by abstract. Relevant manuscripts were read in full text. Results: In total, 23 studies regarding H-FABP in HF were included in this review. Conclusion: While, algorithms already exist in the area of risk stratification for acute pulmonary embolism, there is still no consensus for the routine use of H-FABP in daily clinical practice in HF. At present, the strongest evidence exists for risk evaluation of adverse cardiac events. Other future applications of H-FABP may include early detection of ischemia, worsening of renal failure, and long-term treatment planning.

show abstract

“…They reported that APE patients with a sPESI ≥ 1 had a higher mortality rate than the patients with sPESI < 1 (mortality rates: 8.9% vs. 1.1%). Various imaging techniques such as contrasted computed tomography (CT) scan of the chest, ventilation-perfusion (VQ) nuclear medicine imaging, and echocardiography (both transthoracic and transoesophageal), as well as laboratory parameters such as D-dimer, cardiac troponin, BNP, heart-type fatty acid-binding protein, and growth-differentiating factor-15 (GDF-15) are helpful in diagnosis and prognosis of acute PE [6][7][8][9][10]. It has been shown that the sympathetic nervous system can contribute to the pathogenesis of APE [11,12].…”

Section: Introductionmentioning

confidence: 99%

Plasma catestatin level predicts sPESI score and mortality in acute pulmonary embolism

İzcı

Acar

İnanır

2020

Arch Med Sci Atheroscler Dis

View full text Add to dashboard Cite

Introduction: Acute pulmonary embolism (APE) is an emergent cardiothoracic disorder. The PESI score is used to estimate 30-day mortality in patients diagnosed with non-high-risk APE. Also, there are biomarkers for predicting prognosis and mortality in APE. Catestatin (CST) is accepted as a marker ofsympathetic nervous system activity which has been shown that the sympathetic nervous system activation can contribute pathogenesis in APE. So, we attempt herein to investigate the correlation of PE diagnosis and prognostic determination with plasma CST levels in PE patients. Material and methods: Blood samples were drawn at admission for laboratory assays and CST measurements. Plasma levels of CST were measured by ELISA according to the manufacturer's instruction. Transthoracic echocardiography was performed for the assessment of RV dysfunction using a Toshiba Applio 500 echocardiographic system within 24 h of the admission. Results: Plasma CST levels were higher in patients with APE than in the control group (17.5 ±6.1 ng/ml vs. 27.3 ±5.7 ng/ml, p < 0.001). Plasma CST levels were higher in the sPESI ≥ 1 (n = 72) than in the patients with sPESI < 1 (37.3 ±6.1 vs. 24.2 ±5.3 ng/ml, p < 0.001). There was a positive correlation between CST level and sPESI score (±0.581, p < 0.001). Mortality occurred in 20 patients with sPESI ≥ 1 (27.7%) and in 9 patients with sPESI < 1 (10.2%) (p = 0.010). Receiver operating characteristic (ROC) curve analysis using a cutoff level of 31.2 ng/ml, and the CST level predicted mortality with a sensitivity of 100% and specificity of 52.6% (AUC = 0.883, 95% CI: 0.689-0.921). Furthermore, the CST level was correlated with right ventricular dysfunction. Conclusions: CST can predict sPESI score and mortality in patients with APE.

show abstract

Risk stratification in acute pulmonary embolism with heart-type fatty acid–binding protein: A meta-analysis

Cited by 31 publications

References 28 publications

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)

Heart-Type Fatty Acid-Binding Protein (H-FABP) and Its Role as a Biomarker in Heart Failure: What Do We Know So Far?

Plasma catestatin level predicts sPESI score and mortality in acute pulmonary embolism

Contact Info

Product

Resources

About